Please join us for this in-person event featuring a fireside chat with Stoke Therapeutics' CEO, Edward Kaye, moderated by Tracy Curley, NSTC President and CFO of iSpecimen. Dr. Kaye will share his experiences as an executive in the biotech industry as it faces innovation, commercialization and financial opportunities and challenges. Learn about Dr. Kaye's leadership journey through this critical and everchanging industry!
Doors open at 5:00 pm. The presentation begins at 5:30 pm and will be followed by a networking reception. The entrance cost is $25 for members and $35 for non-members.
Edward Kaye, MD
Ed Kaye, a pediatric neurologist, is the chief executive officer and a director of Stoke Therapeutics. Ed previously served as CEO of Sarepta Therapeutics, where he led the successful push to win FDA approval of Exondys 51, a pioneering drug for Duchenne muscular dystrophy. Before taking on the CEO role at Sarepta, he served as the company’s chief medical officer for six years, leading the drive to develop Exondys 51. He also served on Sarepta’s board of directors. Earlier in his career, Ed spent 10 years at Genzyme Corporation, most recently as group vice president of clinical development, where he supervised clinical research in programs focused on lysosomal storage disease and genetic neurological disorders. Prior to entering the biotech industry, Ed trained in pediatrics, pediatric neurology, and biochemical genetics. Ed earned his B.S. in biology from Loyola University and earned his M.D. at the Loyola University Stritch School of Medicine.
North Shore Technology Council is a 501(c)6 non-profit organization. 100 Cummings Center, Suite 223-F Beverly, MA 01915.
Contact us at email@example.com.